Related Experiment Video
Updated: May 8, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Pathogenic role of diabetes-induced PPAR-α down-regulation in microvascular dysfunction
Abstract:
Two independent clinical studies have reported that fenofibrate, a peroxisome proliferator-activated receptor α (PPARα) agonist, has robust therapeutic effects on microvascular complications of diabetes, including diabetic retinopathy (DR) in type 2 diabetic patients. However, the expression and function of PPARα in the retina are unclear. Here, we demonstrated that PPARα is expressed in multiple cell types in the retina. In both type 1 and type 2 diabetes models, expression of PPARα, but not PPARβ/δ or PPARγ, was significantly down-regulated in the retina. Furthermore, high-glucose medium was sufficient to down-regulate PPARα expression in cultured retinal cells. To further investigate the role of PPARα in DR, diabetes was induced in PPARα knockout (KO) mice and wild-type (WT) mice. Diabetic PPARα KO mice developed more severe DR, as shown by retinal vascular leakage, leukostasis, pericyte loss, capillary degeneration, and over-expression of inflammatory factors, compared with diabetic WT mice. In addition, overexpression of PPARα in the retina of diabetic rats significantly alleviated diabetes-induced retinal vascular leakage and retinal inflammation. Furthermore, PPARα overexpression inhibited endothelial cell migration and proliferation. These findings revealed that diabetes-induced down-regulation of PPARα plays an important role in DR. Up-regulation or activation of PPARα may represent a novel therapeutic strategy for DR.
Insights
Fenofibrate activates peroxisome proliferator-activated receptor alpha (PPARα), crucial for treating diabetic retinopathy (DR). Diabetes lowers PPARα in the retina, worsening DR; restoring PPARα offers a potential therapeutic strategy.
Area of Science:
- Ophthalmology
- Endocrinology
- Molecular Biology
Background:
- Fenofibrate, a PPARα agonist, shows therapeutic effects on diabetic microvascular complications, including diabetic retinopathy (DR).
- The expression and function of PPARα within the retina remain largely uncharacterized.
- PPARα is expressed in various retinal cell types.
Purpose of the Study:
- To investigate the role of PPARα in the pathogenesis of diabetic retinopathy.
- To explore the therapeutic potential of modulating PPARα in DR.
Main Methods:
- Assessed PPARα expression in type 1 and type 2 diabetes models and high-glucose cultured retinal cells.
- Utilized PPARα knockout (KO) and wild-type (WT) mice to study DR development.
- Investigated the effects of PPARα overexpression in diabetic rat retinas.
Main Results:
- PPARα expression was significantly downregulated in diabetic retinas and high-glucose conditions.
- Diabetic PPARα KO mice exhibited exacerbated DR features compared to WT mice.
- PPARα overexpression ameliorated diabetes-induced retinal vascular leakage, inflammation, and inhibited endothelial cell proliferation.
Conclusions:
- Diabetes-induced downregulation of PPARα is a key factor in DR development.
- Upregulation or activation of PPARα presents a promising therapeutic avenue for diabetic retinopathy.
Related Concept Videos
Diabetic Retinopathy
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Diabetic Nephropathy
Type II Diabetes II: Pathophysiology
Diabetic Neuropathy
Type I Diabetes II: Pathophysiology
